Mongkhonmath Niphonh, Olson Phayom Sookaneknun, Puttarak Panupong, Chaiyakunapruk Nathorn, Sawangjit Ratree
J Am Pharm Assoc (2003). 2025 Jan-Feb;65(1):102293. doi: 10.1016/j.japh.2024.102293. Epub 2024 Nov 9.
Pharmacovigilance is essential for patient safety, but underreporting adverse drug reactions (ADRs) is a global challenge.
This review evaluated the effectiveness of strategies for enhancing ADR reporting by healthcare professionals (HCPs).
This systematic review was conducted following the Cochrane and the PRISMA guidelines. Five international databases were searched from inception to December 2023 and updated search to September 2024. Randomized clinical controlled trials (RCTs) and non-RCTs on enhancing ADR reporting were included. The primary outcomes were the number of overall ADR and high-quality ADR reports. Study quality was assessed using the Effective Practice and Organization of Care risk of bias (ROB), and ROBIN-I for RCT, and non-RCT. All data were evaluated using a random-effects model, and heterogeneity was assessed using I statistic and chi-squared tests.
From 1672 studies, 13 studies (10 RCTs, and 3 non-RCTs) with 28,116 participants were included. Two of 10 RCTs had low ROB while the remaining were judged as unclear and moderate ROB. Most studies were in high-income countries, and the main strategy was educating HCPs through workshops. Meta-analysis showed significant increases in overall ADR reporting through educating HCPs with a rate ratio (RR) of 5.09 (95% CI: 3.36-7.71, I = 84.5%, low certainty), and in high-quality reporting with 1.31 (95% CI: 1.09-1.58, I = 0.0%, moderate certainty). Subgroup analysis indicated that educating HCPs through face-to-face workshops combined with the Tawai app (RR:10.5, 95% CI: 8.74-12.61), a face-to-face workshop alone (RR:6.69, 95% CI: 5.43-8.25, I = 0.0%), and repeated telephone (RR:2.59, 95% CI: 1.75-3.84, I = 8.8%) significantly increased the overall number of ADR reports with moderate certainty. Email or letter communications showed no significant effect.
Educating HCPs via interactive strategies like face-to-face workshops with or without a mobile app and repeated phone calls improved ADR reporting. However, long-term, high-quality studies are needed to confirm these findings before recommending widespread implementation in clinical practice, especially in low-and middle-income countries.
药物警戒对患者安全至关重要,但药品不良反应(ADR)报告不足是一项全球性挑战。
本综述评估了提高医疗保健专业人员(HCP)报告ADR的策略的有效性。
本系统综述按照Cochrane和PRISMA指南进行。检索了五个国际数据库,检索时间从建库至2023年12月,并更新检索至2024年9月。纳入了关于提高ADR报告的随机临床对照试验(RCT)和非RCT。主要结局是总体ADR报告数量和高质量ADR报告数量。使用有效实践和护理组织偏倚风险(ROB)评估研究质量,对于RCT和非RCT分别使用ROBIN-I。所有数据均使用随机效应模型进行评估,异质性使用I统计量和卡方检验进行评估。
从1672项研究中,纳入了13项研究(10项RCT和3项非RCT),共28116名参与者。10项RCT中有2项偏倚风险较低,其余被判定为不明确和中度偏倚风险。大多数研究在高收入国家进行,主要策略是通过研讨会对HCP进行培训。荟萃分析显示,通过培训HCP,总体ADR报告显著增加,率比(RR)为5.09(95%CI:3.36 - 7.71,I = 84.5%,低确定性),高质量报告增加,RR为1.31(95%CI:1.09 - 1.58,I = 0.0%,中度确定性)。亚组分析表明,通过面对面研讨会结合Tawai应用程序培训HCP(RR:10.5,95%CI:8.74 - 12.61)、单独的面对面研讨会(RR:6.69,95%CI:5.43 - 8.25,I = 0.0%)以及重复电话沟通(RR:2.59,95%CI:1.75 - 3.84,I = 8.8%)可在中度确定性下显著增加ADR报告的总数。电子邮件或信件沟通未显示出显著效果。
通过面对面研讨会(有无移动应用程序)和重复电话等互动策略培训HCP可改善ADR报告。然而,在推荐在临床实践中广泛实施之前,尤其是在低收入和中等收入国家,需要长期、高质量的研究来证实这些发现。